Repligen Corporation (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Brokerages

Repligen Corporation (NASDAQ:RGEN) has been given a consensus rating of “Moderate Buy” by the fourteen ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $177.9167.

Several brokerages have recently commented on RGEN. Jefferies Financial Group set a $160.00 target price on Repligen and gave the company a “hold” rating in a report on Tuesday, October 28th. Royal Bank Of Canada restated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a report on Tuesday, September 2nd. Evercore ISI raised their target price on shares of Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Hsbc Global Res raised shares of Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st. Finally, HSBC started coverage on shares of Repligen in a research report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price target for the company.

Insider Activity

In related news, Director Karen A. Dawes sold 275 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the transaction, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anthony Hunt sold 20,000 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $154.61, for a total value of $3,092,200.00. Following the sale, the director owned 80,743 shares of the company’s stock, valued at $12,483,675.23. The trade was a 19.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 49,657 shares of company stock worth $7,721,077 over the last quarter. Corporate insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

A number of hedge funds have recently made changes to their positions in the stock. Twin Tree Management LP acquired a new position in Repligen in the 1st quarter valued at approximately $29,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen during the 3rd quarter valued at $29,000. Hantz Financial Services Inc. increased its stake in shares of Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 293 shares during the last quarter. CWM LLC raised its holdings in shares of Repligen by 67.2% during the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 135 shares in the last quarter. Finally, Center for Financial Planning Inc. raised its holdings in shares of Repligen by 34.2% during the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 126 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Trading Up 0.3%

Shares of NASDAQ:RGEN opened at $166.21 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The stock has a market capitalization of $9.36 billion, a price-to-earnings ratio of 8,314.66, a PEG ratio of 3.74 and a beta of 1.11. Repligen has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a 50 day moving average price of $158.60 and a 200 day moving average price of $137.20.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The company had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The company’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, research analysts anticipate that Repligen will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.